EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Risk factors for malignancy and serious infection in patients with inflammatory bowel disease: a retrospective analysis

Daniel Tassone iD, Chamara Basnayake iD, Emily Wright, Mark Lust, Michael A Kamm iD, Ola Niewiadomski iD, Julien Schulberg, Emma Flanagan, Tamie Samyue, Stephanie Fry, Ruth Malcolm, Annalise Stanley und 3 weitere

Internal Medicine Journal · 2024

DOI: 10.1111/imj.16141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Daniel Tassone und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Neoplasms, Colitis, Ulcerative, Crohn Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with inflammatory bowel disease (IBD) are at increased risk of malignancy and infection compared to the general population.

Aims

We aim to identify risk factors for malignancy or serious infection in our IBD cohort.

Methods

Patients with IBD from a single tertiary referral centre were included. Demographic and clinical details, including immunosuppressant exposure, were collected and medical records retrospectively screened for adverse events, including malignancy or infection requiring hospitalisation. Logistic regression was used to evaluate risk factors for adverse events.

Results

Five hundred and forty‐nine patients with IBD (340 Crohn disease (CD) and 209 ulcerative colitis (UC)) were studied. Forty‐eight malignancies, including 39 (81.3%) non‐melanoma skin cancers, 3 (6.3%) haematologic malignancies and 6 (15.4%) solid‐organ malignancies, were identified, and 92 cases of serious infection were detected. IBD duration (odds ratio (OR) = 1.08; 95% confidence interval (CI) = 1.03–1.13) and ileocolonic CD (OR = 4.96; 95% CI = 1.13–21.71) were associated with increased odds of overall cancer. Compared with patients not previously exposed to the given class of immunosuppression assessed, the development of overall malignancy was not higher with thiopurine exposure (OR = 1.00; 95% CI = 0.50–2.24) or anti‐tumour necrosis factor‐alpha (TNF‐α) exposure (OR = 0.78; 95% CI = 0.37–1.64). Similarly, compared with patients not exposed, infection risk was not affected by thiopurine (OR = 0.74; 95% CI = 0.46–1.20) or anti‐TNF exposure (OR = 0.60; 95% CI = 0.38–0.95).

Conclusions

Factors including ileocolonic CD and increasing IBD duration were associated with higher malignancy risk in this cohort. Compared with non‐exposure, patients exposed to thiopurines were not at increased risk of malignancy or serious infection. Similarly, patients exposed to anti‐TNF treatment did not experience increased rates of malignancy or serious infection compared to patients not exposed to this treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesNeoplasmsColitis, UlcerativeCrohn DiseasePurinesSulfhydryl CompoundsHumansRetrospective StudiesTumor Necrosis Factor InhibitorsRisk Factors

Stichwörter der Autor:innen

Crohn diseaseimmunosuppressioninfectionmalignancyulcerative colitis

Substanzen

2-mercaptopurineTumor Necrosis Factor InhibitorsPurinesSulfhydryl Compounds

Autor:innen und Institutionen

  • Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
  • Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.

ORCID-Profile: Daniel Tassone, Chamara Basnayake, Michael A Kamm, Ola Niewiadomski

Zitieren

APA

Tassone, D., Basnayake, C., Wright, E., Lust, M., Kamm, M. A., Niewiadomski, O., Schulberg, J., Flanagan, E., Samyue, T., Fry, S., Malcolm, R., Stanley, A., Thompson, A. J., Connell, W. R., & Ding, N. S. (2024). Risk factors for malignancy and serious infection in patients with inflammatory bowel disease: a retrospective analysis. Internal Medicine Journal. https://doi.org/10.1111/imj.16141

Vancouver

Tassone D, Basnayake C, Wright E, Lust M, Kamm MA, Niewiadomski O, et al. Risk factors for malignancy and serious infection in patients with inflammatory bowel disease: a retrospective analysis. Internal Medicine Journal. 2024. doi:10.1111/imj.16141

BibTeX
@article{Tassone2024,
  author = {Tassone, Daniel and Basnayake, Chamara and Wright, Emily and Lust, Mark and Kamm, Michael A and Niewiadomski, Ola and Schulberg, Julien and Flanagan, Emma and Samyue, Tamie and Fry, Stephanie and Malcolm, Ruth and Stanley, Annalise and Thompson, Alexander J and Connell, William R and Ding, Nik S},
  title = {Risk factors for malignancy and serious infection in patients with inflammatory bowel disease: a retrospective analysis},
  journal = {Internal Medicine Journal},
  year = {2024},
  doi = {10.1111/imj.16141}
}
Kostenlos starten →